

**Diaceutics PLC**  
**("Diaceutics" or the "Company")**

**Notice of results**  
**Analyst briefing**

Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces it will release its interim results for the six months ended 30 June 2019 on Monday 9 September 2019.

**Analyst briefing**

The Company will host a briefing for analysts which will take place at 11.30am on Monday 9 September 2019 in the City of London. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com).

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer  
Philip White, Chief Financial Officer

[www.diaceutics.com](http://www.diaceutics.com)  
via Walbrook PR

**Cenkos Securities plc (Nominated adviser and broker)**

Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

+44 (0) 20 3861 6630

**Walbrook PR**

Anna Dunphy  
Paul McManus

Tel: +44 (0)20 7933 8780 or [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com)

Mob: +44 (0)7876 741 001  
Mob: +44 (0)7980 541 893

**About Diaceutics**

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  
[www.diaceutics.com](http://www.diaceutics.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

NORUBSSRKKAWRAR